MOTS-c: A Peptide Encoded by the Mitochondrial Genome

MOTS-c is a peptide of sixteen amino acids, MRWQEMGYIFYPRKLR, with the molecular formula C101H152N28O22S2 and a molecular weight of approximately 2,175 g/mol. It resolves in PubChem under CID 146675088 and carries CAS 1627580-64-6. As a chemical object it is ordinary - no non-standard residues, no cyclisation, no conjugation.

What makes it unusual is its origin. Nearly every peptide and protein in a human cell is transcribed from nuclear DNA. MOTS-c is not: its coding sequence sits inside the mitochondrial genome, within an open reading frame located in the 12S ribosomal RNA gene. The name encodes this - mitochondrial open reading frame of the twelve S rRNA type-c.

Mitochondria carry their own small circular genome, a remnant of the bacterial ancestry of the organelle, and it was long assumed to encode only the thirteen respiratory-chain subunits, two rRNAs and twenty-two tRNAs. MOTS-c belongs to a small and comparatively recently described class of peptides - humanin is the other well-known member - encoded within that genome outside the canonical thirteen. This is the reason MOTS-c attracted attention: not the size of any reported effect, but the claim that mitochondrial DNA encodes signalling molecules at all.

The 2015 paper by Lee and colleagues is the source of essentially everything specific that can be said about how MOTS-c acts, and its mechanism is more precise than most summaries convey.

The commonly repeated statement is that MOTS-c activates AMP-activated protein kinase, the cell's central low-energy sensor. What the paper reports is a step upstream of that. MOTS-c acts on the folate-methionine cycle, and inhibition of the folate cycle causes 5-aminoimidazole-4-carboxamide ribonucleotide - AICAR - to accumulate. AICAR is an endogenous AMPK activator. AMPK activation is therefore a downstream metabolic consequence of interference with one-carbon metabolism, not a direct action of the peptide on the kinase.

The distinction matters for interpretation. A compound that binds and activates a kinase has a defined pharmacological target; a compound that perturbs a metabolic cycle so that an activating metabolite accumulates has effects that will depend on the metabolic state of the cell, its folate status, and what else is drawing on one-carbon units. It is a less predictable form of action, and it is the one the primary literature describes.

In the same work, treated mice were reported to be resistant to diet-induced obesity and to show improved insulin sensitivity. These are rodent findings and are the origin of most metabolic claims made about the peptide.

The second strand of MOTS-c biology concerns location rather than metabolism. Under metabolic stress, the peptide has been reported to translocate from the cytosol into the nucleus and to influence the transcription of nuclear genes, including sets associated with antioxidant and stress-response elements.

If that holds, the implication is larger than any individual metabolic effect. It would make MOTS-c a mediator of retrograde signalling - information flowing from mitochondria to the nucleus, rather than the nuclear-to-mitochondrial direction that dominates textbook accounts of organelle regulation. A mitochondrially encoded peptide that physically relocates to the nucleus and alters gene expression is a mechanism for the organelle to report its own state.

This is the framing that has driven most of the recent interest, and it is worth separating the framing from the evidence. The relocation and transcriptional effects have been demonstrated in cell systems under experimentally imposed stress. Whether this constitutes a routine physiological signalling channel in intact human tissue, or an observable behaviour under laboratory stress conditions, is not settled by the current literature.

Reynolds and colleagues connected MOTS-c to exercise physiology in 2021. They reported that the peptide increases in skeletal muscle and in circulation in association with exercise, and that administering it to mice improved measures of physical performance, including in older animals. This is the study behind most claims linking MOTS-c to healthspan.

It also contains the only human measurements in the mainstream MOTS-c literature, and their nature should be stated plainly: they are observational samples taken around exercise, showing that endogenous levels change. They are not evidence that administering the peptide to a human does anything. The performance findings are entirely from mice.

The other human contribution is genetic. Fuku and colleagues examined a variant that alters the MOTS-c coding sequence and reported an association with exceptional longevity in a Japanese cohort, most apparent in men. Their own title carries a question mark, which is appropriate - associations of this kind are tied to particular mitochondrial haplogroups and to particular populations, and they have historically been difficult to replicate across ancestries. Read carefully, this is evidence that the MOTS-c sequence is under some selective relevance, not evidence that more MOTS-c produces longer life.

There is no published controlled trial of administered MOTS-c in humans. That is the central fact about its evidence base, and no amount of mechanistic elegance substitutes for it. Human pharmacokinetics are similarly unpublished - absorption, distribution, half-life and clearance for exogenously supplied peptide are not characterised in the indexed literature.

The receptor question is open in an interesting way. MOTS-c is described as acting on an intracellular metabolic cycle and, separately, as relocating to the nucleus. Neither of those is a cell-surface receptor interaction, and how an exogenously supplied peptide reaches the intracellular compartments where these actions occur is not well described. For a molecule that normally originates inside the cell, this is not a trivial gap.

Finally, the translation from mouse to human is unusually uncertain here. Mitochondrial genetics differ between species and between human haplogroups, one-carbon metabolism is strongly influenced by diet and folate status, and the reported effects are downstream of a metabolic cycle rather than of a defined receptor. Long-term toxicology in humans is absent. The compound is best understood as an active research subject in mitochondrial biology rather than as an intervention with established human effects.